膜联蛋白A1调控头颈癌EGFR活性并改变含EGFR的肿瘤来源外泌体
该研究探讨膜联蛋白A1(ANXA1)在头颈鳞状细胞癌(HNSCC)中的作用。通过RNA测序和免疫组化发现ANXA1在肿瘤组织中表达下调,功能实验表明其通过细胞内形式抑制增殖,并调控EGFR磷酸化及外泌体磷酸化EGFR释放。结论认为ANXA1是HNSCC的抑癌因子和潜在预后生物标志物。
要点
- ANXA1在头颈鳞癌组织中mRNA和蛋白水平均下调。
- ANXA1通过细胞内形式发挥抗增殖作用。
- ANXA1下调增加EGFR磷酸化及下游PI3K-AKT信号活性。
核心结论
- ANXA1在HNSCC中作为抑癌因子发挥作用。
- ANXA1参与调控EGFR活性及外泌体磷酸化EGFR的释放。
- ANXA1可能成为重要的预后生物标志物。
研究设计与样本
- 研究采用RNA测序分析ANXA1 mRNA表达,免疫组化检测蛋白表达。
- 通过功能获得和丧失实验分析ANXA1对细胞增殖、EGFR信号激活及外泌体产生的影响。
主要发现
- ANXA1在头颈癌组织中mRNA和蛋白水平均下调。
- ANXA1的抗增殖效应由细胞内形式介导。
- ANXA1下调导致EGFR磷酸化及活性增加,并激活下游PI3K-AKT信号。
- ANXA1调控影响外泌体产生及外泌体磷酸化EGFR的释放。
临床怎么用
- ANXA1可能作为HNSCC的预后生物标志物进行进一步评估。
- ANXA1对EGFR信号和外泌体磷酸化EGFR的调控提示其与EGFR靶向治疗潜在相关。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Head and neck squamous cell carcinoma (HNSCC) is the 6th most common cancer with approximately half a million cases diagnosed each year worldwide. HNSCC has a poor survival rate which has not improved for over 30 years. The molecular pathogenesis of HNSCCs remains largely unresolved; there is high prevalence of p53 mutations and EGFR overexpression; however, the contribution of these molecular changes to disease development and/or progression remains unknown. We have recently identified microRNA miR-196a to be highly overexpressed in HNSCC with poor prognosis. Oncogenic miR-196a directly targets Annexin A1 (ANXA1). Although increased ANXA1 expression levels have been associated with breast cancer development, its role in HNSCC is debatable and its functional contribution to HNSCC development remains unclear. METHODS: ANXA1 mRNA and protein expression levels were determined by RNA Seq analysis and immunohistochemistry, respectively. Gain- and loss-of-function studies were performed to analyse the effects of ANXA1 modulation on cell proliferation, mechanism of activation of EGFR signalling as well as on exosome production and exosomal phospho-EGFR. RESULTS: ANXA1 was found to be downregulated in head and neck cancer tissues, both at mRNA and protein level. Its anti-proliferative effects were mediated through the intracellular form of the protein. Importantly, ANXA1 downregulation resulted in increased phosphorylation and activity of EGFR and its downstream PI3K-AKT signalling. Additionally, ANXA1 modulation affected exosome production and influenced the release of exosomal phospho-EGFR. CONCLUSIONS: ANXA1 acts as a tumour suppressor in HNSCC. It is involved in the regulation of EGFR activity and exosomal phospho-EGFR release and could be an important prognostic biomarker.
引用
- Raulf N, Lucarelli P, Thavaraj S, et al. Annexin A1 regulates EGFR activity and alters EGFR-containing tumour-derived exosomes in head and neck cancers. Eur J Cancer. 2018. PMID: 30142511. doi:10.1016/j.ejca.2018.07.123
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。